Unknown

Dataset Information

0

Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.


ABSTRACT: Prospective studies of antibodies to multiple Epstein-Barr virus (EBV) proteins and EBV neutralizing antibodies in the same individuals before, during, and after primary EBV infection have not been reported. We studied antibody responses to EBV in college students who acquired primary EBV infection during prospective surveillance and correlated the kinetics of antibody response with the severity of disease. Neutralizing antibodies and enzyme-linked immunosorbent assay (ELISA) antibodies to gp350, the major target of neutralizing antibody, reached peak levels at medians of 179 and 333 days after the onset of symptoms of infectious mononucleosis, respectively. No clear correlation was found between the severity of the symptoms of infectious mononucleosis and the peak levels of antibody to individual viral proteins or to neutralizing antibody. In summary, we found that titers of neutralizing antibody and antibodies to multiple EBV proteins increase over many months after primary infection with EBV.

SUBMITTER: Bu W 

PROVIDER: S-EPMC4820504 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.

Bu Wei W   Hayes Gregory M GM   Liu Hui H   Gemmell Lorraine L   Schmeling David O DO   Radecki Pierce P   Aguilar Fiona F   Burbelo Peter D PD   Woo Jennifer J   Balfour Henry H HH   Cohen Jeffrey I JI  

Clinical and vaccine immunology : CVI 20160404 4


Prospective studies of antibodies to multiple Epstein-Barr virus (EBV) proteins and EBV neutralizing antibodies in the same individuals before, during, and after primary EBV infection have not been reported. We studied antibody responses to EBV in college students who acquired primary EBV infection during prospective surveillance and correlated the kinetics of antibody response with the severity of disease. Neutralizing antibodies and enzyme-linked immunosorbent assay (ELISA) antibodies to gp350  ...[more]

Similar Datasets

| S-EPMC6901265 | biostudies-literature
| S-EPMC8272980 | biostudies-literature
| S-EPMC8176630 | biostudies-literature
| S-EPMC8880155 | biostudies-literature
| S-EPMC9481173 | biostudies-literature
| S-EPMC10412493 | biostudies-literature
| S-EPMC9170382 | biostudies-literature
| S-EPMC6917282 | biostudies-literature
| S-EPMC110276 | biostudies-literature
| S-EPMC2715772 | biostudies-literature